These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 16675587

  • 1. The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide.
    O'Connor OA, Smith EA, Toner LE, Teruya-Feldstein J, Frankel S, Rolfe M, Wei X, Liu S, Marcucci G, Chan KK, Chanan-Khan A.
    Clin Cancer Res; 2006 May 01; 12(9):2902-11. PubMed ID: 16675587
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rötzer S, Rademacher J, Jakob C, Fleissner C, Kuckelkorn U, Kloetzel PM, Sezer O.
    Eur J Haematol; 2008 Feb 01; 80(2):133-42. PubMed ID: 18005386
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins.
    Wolter KG, Verhaegen M, Fernández Y, Nikolovska-Coleska Z, Riblett M, de la Vega CM, Wang S, Soengas MS.
    Cell Death Differ; 2007 Sep 01; 14(9):1605-16. PubMed ID: 17541428
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells.
    Duechler M, Linke A, Cebula B, Shehata M, Schwarzmeier JD, Robak T, Smolewski P.
    Eur J Haematol; 2005 May 01; 74(5):407-17. PubMed ID: 15813915
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
    von Metzler I, Heider U, Mieth M, Lamottke B, Kaiser M, Jakob C, Sezer O.
    Exp Cell Res; 2009 Aug 15; 315(14):2471-8. PubMed ID: 19410573
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Apoptosis, Bcl-2 antisense, and cancer therapy.
    Piro LD.
    Oncology (Williston Park); 2004 Nov 15; 18(13 Suppl 10):5-10. PubMed ID: 15651171
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors.
    Chu S, Alexiadis M, Fuller PJ.
    Reprod Sci; 2009 Apr 15; 16(4):397-407. PubMed ID: 19087975
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.
    Horton TM, Gannavarapu A, Blaney SM, D'Argenio DZ, Plon SE, Berg SL.
    Cancer Chemother Pharmacol; 2006 Jul 15; 58(1):13-23. PubMed ID: 16292537
    [Abstract] [Full Text] [Related]

  • 15. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
    Ishii Y, Pirkmaier A, Alvarez JV, Frank DA, Keselman I, Logothetis D, Mandeli J, O'Connell MJ, Waxman S, Germain D.
    J Natl Cancer Inst; 2006 Sep 06; 98(17):1238-47. PubMed ID: 16954476
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
    Heider U, Rademacher J, Lamottke B, Mieth M, Moebs M, von Metzler I, Assaf C, Sezer O.
    Eur J Haematol; 2009 Jun 06; 82(6):440-9. PubMed ID: 19220424
    [Abstract] [Full Text] [Related]

  • 18. Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab.
    Ramanarayanan J, Hernandez-Ilizaliturri FJ, Chanan-Khan A, Czuczman MS.
    Br J Haematol; 2004 Dec 06; 127(5):519-30. PubMed ID: 15566355
    [Abstract] [Full Text] [Related]

  • 19. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
    Shringarpure R, Catley L, Bhole D, Burger R, Podar K, Tai YT, Kessler B, Galardy P, Ploegh H, Tassone P, Hideshima T, Mitsiades C, Munshi NC, Chauhan D, Anderson KC.
    Br J Haematol; 2006 Jul 06; 134(2):145-56. PubMed ID: 16846475
    [Abstract] [Full Text] [Related]

  • 20. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
    Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL, Salgia R, Sugarbaker DJ, Bueno R.
    Cancer Chemother Pharmacol; 2008 Apr 06; 61(4):549-58. PubMed ID: 17522864
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.